Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

UROGEN PHARMA LTD.

(URGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

UroGen Pharma : to Present at the 2021 Cantor Virtual Global Healthcare Conference

09/23/2021 | 08:07am EDT

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it will present at the Cantor Fitzgerald 2021 Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 3:20 p.m. Eastern Time.

A live webcast of the presentation will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of the webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.


© Business Wire 2021
All news about UROGEN PHARMA LTD.
10/06UROGEN PHARMA : The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study..
AQ
10/05UROGEN PHARMA : The Journal of Urology Publishes Results of UroGen Pharma's Phase 2b Study..
BU
10/05The Journal of Urology Publishes Results of UroGen Pharma Ltd.'s Phase 2B Study of UGN-..
CI
09/23UROGEN PHARMA : to Present at the 2021 Cantor Virtual Global Healthcare Conference
BU
09/13UROGEN PHARMA : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
AQ
09/13UROGEN PHARMA LTD. : Other Events (form 8-K)
AQ
09/13UROGEN PHARMA : Presents Data Showcasing Novel Clinical Data at 2021 American Urological A..
BU
09/13UroGen Pharma Ltd. Announces Final Data from Two Key Trials, Evaluating the Safety and ..
CI
09/10UROGEN PHARMA : to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BU
09/06UROGEN PHARMA : Announces Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
More news
Analyst Recommendations on UROGEN PHARMA LTD.
More recommendations
Financials (USD)
Sales 2021 54,5 M - -
Net income 2021 -114 M - -
Net cash 2021 27,5 M - -
P/E ratio 2021 -3,48x
Yield 2021 -
Capitalization 382 M 382 M -
EV / Sales 2021 6,50x
EV / Sales 2022 2,50x
Nbr of Employees 190
Free-Float 89,7%
Chart UROGEN PHARMA LTD.
Duration : Period :
UroGen Pharma Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UROGEN PHARMA LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 17,08 $
Average target price 42,60 $
Spread / Average Target 149%
EPS Revisions
Managers and Directors
Elizabeth Barrett President, Chief Executive Officer & Director
Molly Henderson Chief Financial & Accounting Officer
Arie S. Belldegrun Chairman
Moran Mieron Director-Research & Pre-Clinical Affairs
Mark P. Schoenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
UROGEN PHARMA LTD.-5.22%382
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610